The new cream, which is part of the Mucodis range of in-licensed patented medical devices, will treat of the side effects experienced by patients undergoing the treatment of cancer.
Around 352,000 patients in the UK are diagnosed annually with cancer and many experience painful or unpleasant side effects as they progress with their treatment.
Mucodis range provides the NHS with prescribable products to address multiple affects associated with cancer treatments including mucositis, radiation-induced dermatitis, vulvovaginitis and proctitis.
With an option to extend beyond the initial period, Colonis has been granted an exclusive distribution licence for all its products for five years.
Since last November, the company has launched the Mucodis mouthwash and oral mucosal spray, Mucodis dermal spray and Mucodis rectal gel.
Quantum Pharma CEO and chief financial officer Chris Rigg said: "We are pleased to launch the Mucodis Vaginal Cream to help treat the unpleasant and painful side effects of cancer treatment.
“This completes the initial range of our Mucodis® branded range of unique, cost effective and patented range of medical devices for the treatment of some of the side effects of oncology treatment.”
Image: Quantum Pharma’s Mucodis branded range. Photo: courtesy of Quantum Pharma Group Limited.
